Arvinas, Inc. (ARVN)

SEC filings show ARVN is well-funded (cash/cash equivalents and marketable securities ~$567.9M at 2026-06-30; current ratio ~7.91; runway guided into 2H 2028) but still structurally cash-flow negative (FY2025 operating cash burn ~$273.8M, capex ~$1.9M). Results inflected sharply in 2026 (Q2’26 revenue ~$249.7M and net income ~$169.4M tied to collaboration/licensing activity), yet durability is uncertain and biotech clinical/regulatory risk remains high. Overall: mixed fundamentals (score 3).

Dominant catalyst is the announced Q2 print (2026-08-04) — a decisive beat (EPS $2.58 vs −$0.38 est., revenue $249.7M, $169.4M net income on VEPPANU/Rigel/Pfizer milestones) that in-window coverage scored clearly positive — offset by a same-day disclosed ARV-102 Phase Ib clinical hold; sentiment delta improving (neutral baseline ≈0.00 → last-14d +0.32 bullish); moderate red-flag cap applied for conflicting catalyst signals.

Price 8.30 sits below every key moving average (SMA20 8.91, SMA50 8.70, SMA200 10.37, EMA9 8.46, EMA21 8.70, WMA9 8.32) with MACD negative and below zero (line -0.18, signal -0.06, histogram -0.11) and ADX at 17.84 showing no trend strength; RSI 39.21 and Williams %R -84.76 mark an oversold tape, but this is a weak-bearish oversold condition, not a bullish setup. Any pullback/oversold limit is blocked as countertrend (price below the SMA50 with MACD < 0, and below a declining SMA200 without a momentum reclaim), and no breakout stop qualifies because there is no confirmed strength to buy above the 8.46 swing high. Technical score 2 (bounce-only).